Does the media favor OPK or CLDX?

In the previous week, OPKO Health had 1 more articles in the media than Celldex Therapeutics. MarketBeat recorded 5 mentions for OPKO Health and 4 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.62 beat OPKO Health's score of -0.03 indicating that Celldex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OPKO Health 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Celldex Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor OPK or BCRX?

In the previous week, BioCryst Pharmaceuticals had 4 more articles in the media than OPKO Health. MarketBeat recorded 9 mentions for BioCryst Pharmaceuticals and 5 mentions for OPKO Health. BioCryst Pharmaceuticals' average media sentiment score of 1.15 beat OPKO Health's score of -0.03 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OPKO Health 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral BioCryst Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ZBIO or OPK?

In the previous week, Zenas BioPharma had 1 more articles in the media than OPKO Health. MarketBeat recorded 6 mentions for Zenas BioPharma and 5 mentions for OPKO Health. Zenas BioPharma's average media sentiment score of 0.68 beat OPKO Health's score of -0.03 indicating that Zenas BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OPKO Health 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, OPK or INVA?

Innoviva has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OPKO Health $581.12M 1.58 -$225.68M -$0.27 N/A Innoviva $411.33M 3.94 $271.17M $6.01 3.65

Is OPK or INVA more profitable?

Innoviva has a net margin of 119.89% compared to OPKO Health's net margin of -36.63%. Innoviva's return on equity of 33.33% beat OPKO Health's return on equity. Company Net Margins Return on Equity Return on Assets OPKO Health -36.63% -16.78% -10.98% Innoviva 119.89% 33.33% 22.67%

Does the media refer more to OPK or INVA?

In the previous week, OPKO Health had 2 more articles in the media than Innoviva. MarketBeat recorded 5 mentions for OPKO Health and 3 mentions for Innoviva. Innoviva's average media sentiment score of 1.37 beat OPKO Health's score of -0.03 indicating that Innoviva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OPKO Health 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Innoviva 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, NVAX or OPK?

Novavax has higher revenue and earnings than OPKO Health. Novavax is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $1.12B 1.22 $440.30M -$0.58 N/A OPKO Health $581.12M 1.58 -$225.68M -$0.27 N/A

Is NVAX or OPK more profitable?

Novavax has a net margin of -14.73% compared to OPKO Health's net margin of -36.63%. Novavax's return on equity of -14.82% beat OPKO Health's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -14.73% -14.82% 1.23% OPKO Health -36.63% -16.78% -10.98%

Does the media refer more to NVAX or OPK?

In the previous week, Novavax had 11 more articles in the media than OPKO Health. MarketBeat recorded 16 mentions for Novavax and 5 mentions for OPKO Health. Novavax's average media sentiment score of 0.91 beat OPKO Health's score of -0.03 indicating that Novavax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive OPKO Health 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

OPKO Health (OPK) Competitors

$1.22 -0.01 (-0.41%)

As of 01:14 PM Eastern

Compare

OPK vs. CLDX, BCRX, ZBIO, INVA, and NVAX

Should you buy OPKO Health stock or one of its competitors? MarketBeat compares OPKO Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with OPKO Health include Celldex Therapeutics (CLDX), BioCryst Pharmaceuticals (BCRX), Zenas BioPharma (ZBIO), Innoviva (INVA), and Novavax (NVAX). These companies are all part of the "biotechnology" industry.

How does OPKO Health compare to Celldex Therapeutics?

OPKO Health (NASDAQ:OPK) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

OPKO Health has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$581.12M	1.58	-$225.68M	-$0.27	N/A
Celldex Therapeutics	$1.54M	1,960.62	-$258.76M	-$4.26	N/A

64.6% of OPKO Health shares are owned by institutional investors. 44.7% of OPKO Health shares are owned by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Celldex Therapeutics has a net margin of 0.00% compared to OPKO Health's net margin of -36.63%. OPKO Health's return on equity of -16.78% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OPKO Health	-36.63%	-16.78%	-10.98%
Celldex Therapeutics	N/A	-50.72%	-46.59%

OPKO Health presently has a consensus price target of $1.55, suggesting a potential upside of 27.57%. Celldex Therapeutics has a consensus price target of $49.30, suggesting a potential upside of 28.16%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Celldex Therapeutics is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

OPKO Health has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

In the previous week, OPKO Health had 1 more articles in the media than Celldex Therapeutics. MarketBeat recorded 5 mentions for OPKO Health and 4 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 1.62 beat OPKO Health's score of -0.03 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OPKO Health	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Celldex Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

OPKO Health beats Celldex Therapeutics on 10 of the 17 factors compared between the two stocks.

How does OPKO Health compare to BioCryst Pharmaceuticals?

OPKO Health (NASDAQ:OPK) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

64.6% of OPKO Health shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 44.7% of OPKO Health shares are owned by insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

OPKO Health has a net margin of -36.63% compared to BioCryst Pharmaceuticals' net margin of -51.71%. OPKO Health's return on equity of -16.78% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OPKO Health	-36.63%	-16.78%	-10.98%
BioCryst Pharmaceuticals	-51.71%	-76.36%	60.12%

OPKO Health presently has a consensus price target of $1.55, suggesting a potential upside of 27.57%. BioCryst Pharmaceuticals has a consensus price target of $20.80, suggesting a potential upside of 121.39%. Given BioCryst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe BioCryst Pharmaceuticals is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
BioCryst Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67

OPKO Health has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

BioCryst Pharmaceuticals has higher revenue and earnings than OPKO Health. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$581.12M	1.58	-$225.68M	-$0.27	N/A
BioCryst Pharmaceuticals	$874.84M	2.73	$263.86M	-$1.78	N/A

In the previous week, BioCryst Pharmaceuticals had 4 more articles in the media than OPKO Health. MarketBeat recorded 9 mentions for BioCryst Pharmaceuticals and 5 mentions for OPKO Health. BioCryst Pharmaceuticals' average media sentiment score of 1.15 beat OPKO Health's score of -0.03 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OPKO Health	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
BioCryst Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioCryst Pharmaceuticals beats OPKO Health on 10 of the 16 factors compared between the two stocks.

How does OPKO Health compare to Zenas BioPharma?

Zenas BioPharma (NASDAQ:ZBIO) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

64.6% of OPKO Health shares are owned by institutional investors. 22.0% of Zenas BioPharma shares are owned by company insiders. Comparatively, 44.7% of OPKO Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Zenas BioPharma had 1 more articles in the media than OPKO Health. MarketBeat recorded 6 mentions for Zenas BioPharma and 5 mentions for OPKO Health. Zenas BioPharma's average media sentiment score of 0.68 beat OPKO Health's score of -0.03 indicating that Zenas BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zenas BioPharma	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OPKO Health	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Zenas BioPharma has a net margin of 0.00% compared to OPKO Health's net margin of -36.63%. OPKO Health's return on equity of -16.78% beat Zenas BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-99.99%	-58.06%
OPKO Health	-36.63%	-16.78%	-10.98%

OPKO Health has higher revenue and earnings than Zenas BioPharma. OPKO Health is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zenas BioPharma	N/A	N/A	-$377.74M	-$8.47	N/A
OPKO Health	$581.12M	1.58	-$225.68M	-$0.27	N/A

Zenas BioPharma presently has a consensus target price of $44.29, indicating a potential upside of 57.26%. OPKO Health has a consensus target price of $1.55, indicating a potential upside of 27.57%. Given Zenas BioPharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Zenas BioPharma is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Zenas BioPharma has a beta of -0.96, meaning that its share price is 196% less volatile than the broader market. Comparatively, OPKO Health has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market.

Summary

OPKO Health beats Zenas BioPharma on 8 of the 15 factors compared between the two stocks.

How does OPKO Health compare to Innoviva?

OPKO Health (NASDAQ:OPK) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

Innoviva has a net margin of 119.89% compared to OPKO Health's net margin of -36.63%. Innoviva's return on equity of 33.33% beat OPKO Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OPKO Health	-36.63%	-16.78%	-10.98%
Innoviva	119.89%	33.33%	22.67%

OPKO Health currently has a consensus target price of $1.55, suggesting a potential upside of 27.57%. Innoviva has a consensus target price of $36.20, suggesting a potential upside of 65.03%. Given Innoviva's stronger consensus rating and higher possible upside, analysts plainly believe Innoviva is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Innoviva has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OPKO Health	$581.12M	1.58	-$225.68M	-$0.27	N/A
Innoviva	$411.33M	3.94	$271.17M	$6.01	3.65

In the previous week, OPKO Health had 2 more articles in the media than Innoviva. MarketBeat recorded 5 mentions for OPKO Health and 3 mentions for Innoviva. Innoviva's average media sentiment score of 1.37 beat OPKO Health's score of -0.03 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OPKO Health	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Innoviva	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OPKO Health has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market. Comparatively, Innoviva has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

64.6% of OPKO Health shares are owned by institutional investors. Comparatively, 99.1% of Innoviva shares are owned by institutional investors. 44.7% of OPKO Health shares are owned by insiders. Comparatively, 2.0% of Innoviva shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Innoviva beats OPKO Health on 12 of the 16 factors compared between the two stocks.

How does OPKO Health compare to Novavax?

Novavax (NASDAQ:NVAX) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

53.0% of Novavax shares are held by institutional investors. Comparatively, 64.6% of OPKO Health shares are held by institutional investors. 1.6% of Novavax shares are held by insiders. Comparatively, 44.7% of OPKO Health shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Novavax has a net margin of -14.73% compared to OPKO Health's net margin of -36.63%. Novavax's return on equity of -14.82% beat OPKO Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
OPKO Health	-36.63%	-16.78%	-10.98%

Novavax has higher revenue and earnings than OPKO Health. Novavax is trading at a lower price-to-earnings ratio than OPKO Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.22	$440.30M	-$0.58	N/A
OPKO Health	$581.12M	1.58	-$225.68M	-$0.27	N/A

Novavax presently has a consensus target price of $13.00, indicating a potential upside of 56.53%. OPKO Health has a consensus target price of $1.55, indicating a potential upside of 27.57%. Given Novavax's stronger consensus rating and higher possible upside, research analysts plainly believe Novavax is more favorable than OPKO Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.40
OPKO Health	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Novavax has a beta of 2.43, indicating that its share price is 143% more volatile than the broader market. Comparatively, OPKO Health has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market.

In the previous week, Novavax had 11 more articles in the media than OPKO Health. MarketBeat recorded 16 mentions for Novavax and 5 mentions for OPKO Health. Novavax's average media sentiment score of 0.91 beat OPKO Health's score of -0.03 indicating that Novavax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
OPKO Health	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Novavax beats OPKO Health on 12 of the 17 factors compared between the two stocks.

Get OPKO Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OPK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OPK vs. The Competition

Export

Metric	OPKO Health	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$917.44M	$7.44B	$6.78B	$12.59B
Dividend Yield	N/A	1.31%	2.68%	8.43%
P/E Ratio	-4.50	50.45	27.11	24.33
Price / Sales	1.58	45.49	525.10	92.04
Price / Cash	N/A	26.31	48.59	59.39
Price / Book	0.73	7.20	10.82	6.30
Net Income	-$225.68M	$162.30M	$3.59B	$331.45M
7 Day Performance	-13.83%	0.27%	-1.53%	-0.08%
1 Month Performance	-13.21%	-0.64%	2.75%	-0.96%
1 Year Performance	-8.65%	7.55%	28.40%	19.89%

OPKO Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OPK OPKO Health	2.0993 of 5 stars	$1.22 -0.4%	$1.55 +27.6%	-9.0%	$917.44M	$581.12M	N/A	1,373	Analyst Revision
CLDX Celldex Therapeutics	2.712 of 5 stars	$37.95 -1.1%	$49.30 +29.9%	+63.4%	$3.01B	$1.54M	N/A	150	Analyst Upgrade
BCRX BioCryst Pharmaceuticals	3.1702 of 5 stars	$10.17 +3.4%	$21.67 +113.0%	+8.7%	$2.50B	$874.84M	N/A	530	Positive News Analyst Forecast
ZBIO Zenas BioPharma	3.507 of 5 stars	$26.45 -2.9%	$44.29 +67.4%	+124.5%	$1.72B	$10M	N/A	N/A
INVA Innoviva	3.7526 of 5 stars	$21.82 -2.2%	$36.20 +65.9%	+11.0%	$1.65B	$411.33M	3.63	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OPK) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OPKO Health (OPK) Competitors

OPK vs. CLDX, BCRX, ZBIO, INVA, and NVAX

How does OPKO Health compare to Celldex Therapeutics?

Summary

How does OPKO Health compare to BioCryst Pharmaceuticals?

Summary

How does OPKO Health compare to Zenas BioPharma?

Summary

How does OPKO Health compare to Innoviva?

Summary

How does OPKO Health compare to Novavax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPK vs. The Competition

OPKO Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OPKO Health (OPK) Competitors

OPK vs. CLDX, BCRX, ZBIO, INVA, and NVAX

How does OPKO Health compare to Celldex Therapeutics?

Which has preferable earnings and valuation, OPK or CLDX?

Do insiders and institutionals have more ownership in OPK or CLDX?

Is OPK or CLDX more profitable?

Do analysts prefer OPK or CLDX?

Which has more volatility & risk, OPK or CLDX?

Does the media favor OPK or CLDX?

Summary

How does OPKO Health compare to BioCryst Pharmaceuticals?

Do institutionals and insiders have more ownership in OPK or BCRX?

Is OPK or BCRX more profitable?

Do analysts prefer OPK or BCRX?

Which has more risk & volatility, OPK or BCRX?

Which has stronger earnings & valuation, OPK or BCRX?

Does the media favor OPK or BCRX?

Summary

How does OPKO Health compare to Zenas BioPharma?

Do institutionals & insiders believe in ZBIO or OPK?

Does the media prefer ZBIO or OPK?

Is ZBIO or OPK more profitable?

Which has stronger valuation & earnings, ZBIO or OPK?

Do analysts rate ZBIO or OPK?

Which has more volatility & risk, ZBIO or OPK?

Summary

How does OPKO Health compare to Innoviva?

Is OPK or INVA more profitable?

Do analysts recommend OPK or INVA?

Which has preferable earnings and valuation, OPK or INVA?

Does the media refer more to OPK or INVA?

Which has more risk & volatility, OPK or INVA?

Do insiders & institutionals have more ownership in OPK or INVA?

Summary

How does OPKO Health compare to Novavax?

Do insiders and institutionals believe in NVAX or OPK?

Is NVAX or OPK more profitable?

Which has stronger valuation & earnings, NVAX or OPK?

Do analysts recommend NVAX or OPK?

Which has more risk and volatility, NVAX or OPK?

Does the media refer more to NVAX or OPK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OPK vs. The Competition

OPKO Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools